Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

MRE11 stability is regulated by CK2-dependent interaction with R2TP complex

P. von Morgen, K. Burdova, TG. Flower, NJ. O'Reilly, SJ. Boulton, SJ. Smerdon, L. Macurek, Z. Hořejší,

. 2017 ; 36 (34) : 4943-4950. [pub] 20170424

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17030865

The MRN (MRE11-RAD50-NBS1) complex is essential for repair of DNA double-strand breaks and stalled replication forks. Mutations of the MRN complex subunit MRE11 cause the hereditary cancer-susceptibility disease ataxia-telangiectasia-like disorder (ATLD). Here we show that MRE11 directly interacts with PIH1D1, a subunit of heat-shock protein 90 cochaperone R2TP complex, which is required for the assembly of large protein complexes, such as RNA polymerase II, small nucleolar ribonucleoproteins and mammalian target of rapamycin complex 1. The MRE11-PIH1D1 interaction is dependent on casein kinase 2 (CK2) phosphorylation of two acidic sequences within the MRE11 C terminus containing serines 558/561 and 688/689. Conversely, the PIH1D1 phospho-binding domain PIH-N is required for association with MRE11 phosphorylated by CK2. Consistent with these findings, depletion of PIH1D1 resulted in MRE11 destabilization and affected DNA-damage repair processes dependent on MRE11. Additionally, mutations of serines 688/689, which abolish PIH1D1 binding, also resulted in decreased MRE11 stability. As depletion of R2TP frequently leads to instability of its substrates and as truncation mutation of MRE11 lacking serines 688/689 leads to decreased levels of the MRN complex both in ATLD patients and an ATLD mouse model, our results suggest that the MRN complex is a novel R2TP complex substrate and that their interaction is regulated by CK2 phosphorylation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17030865
003      
CZ-PrNML
005      
20171101105424.0
007      
ta
008      
171025s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/onc.2017.99 $2 doi
035    __
$a (PubMed)28436950
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a von Morgen, P $u Department of Cancer Cell Biology, Institute of Molecular Genetics of the ASCR, Prague, Czech Republic. Faculty of Science, Charles University, Prague, Czech Republic.
245    10
$a MRE11 stability is regulated by CK2-dependent interaction with R2TP complex / $c P. von Morgen, K. Burdova, TG. Flower, NJ. O'Reilly, SJ. Boulton, SJ. Smerdon, L. Macurek, Z. Hořejší,
520    9_
$a The MRN (MRE11-RAD50-NBS1) complex is essential for repair of DNA double-strand breaks and stalled replication forks. Mutations of the MRN complex subunit MRE11 cause the hereditary cancer-susceptibility disease ataxia-telangiectasia-like disorder (ATLD). Here we show that MRE11 directly interacts with PIH1D1, a subunit of heat-shock protein 90 cochaperone R2TP complex, which is required for the assembly of large protein complexes, such as RNA polymerase II, small nucleolar ribonucleoproteins and mammalian target of rapamycin complex 1. The MRE11-PIH1D1 interaction is dependent on casein kinase 2 (CK2) phosphorylation of two acidic sequences within the MRE11 C terminus containing serines 558/561 and 688/689. Conversely, the PIH1D1 phospho-binding domain PIH-N is required for association with MRE11 phosphorylated by CK2. Consistent with these findings, depletion of PIH1D1 resulted in MRE11 destabilization and affected DNA-damage repair processes dependent on MRE11. Additionally, mutations of serines 688/689, which abolish PIH1D1 binding, also resulted in decreased MRE11 stability. As depletion of R2TP frequently leads to instability of its substrates and as truncation mutation of MRE11 lacking serines 688/689 leads to decreased levels of the MRN complex both in ATLD patients and an ATLD mouse model, our results suggest that the MRN complex is a novel R2TP complex substrate and that their interaction is regulated by CK2 phosphorylation.
650    _2
$a zvířata $7 D000818
650    _2
$a proteiny regulující apoptózu $x metabolismus $7 D051017
650    _2
$a teleangiektatická ataxie $x metabolismus $7 D001260
650    _2
$a ATM protein $x metabolismus $7 D064007
650    _2
$a kaseinkinasa II $x metabolismus $7 D047390
650    _2
$a buněčné jádro $x metabolismus $7 D002467
650    _2
$a poškození DNA $x fyziologie $7 D004249
650    _2
$a oprava DNA $x fyziologie $7 D004260
650    _2
$a enzymy opravy DNA $x metabolismus $7 D045643
650    _2
$a DNA vazebné proteiny $x metabolismus $7 D004268
650    _2
$a proteiny teplotního šoku $x metabolismus $7 D006360
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    _2
$a mutace $x fyziologie $7 D009154
650    _2
$a jaderné proteiny $x metabolismus $7 D009687
650    _2
$a fosforylace $x fyziologie $7 D010766
650    _2
$a vazba proteinů $x fyziologie $7 D011485
650    _2
$a RNA-polymerasa II $x metabolismus $7 D012319
650    _2
$a ribonukleoproteiny malé jadérkové $x metabolismus $7 D020718
650    _2
$a serin $x metabolismus $7 D012694
650    _2
$a TOR serin-threoninkinasy $x metabolismus $7 D058570
655    _2
$a časopisecké články $7 D016428
700    1_
$a Burdova, K $u Department of Cancer Cell Biology, Institute of Molecular Genetics of the ASCR, Prague, Czech Republic.
700    1_
$a Flower, T G $u Structural Biology of DNA-damage Signalling Laboratory, The Francis Crick Institute, London,UK.
700    1_
$a O'Reilly, N J $u Peptide Chemistry, The Francis Crick Institute, London, UK.
700    1_
$a Boulton, S J $u DSB Repair Metabolism Laboratory, The Francis Crick Institute, London, UK.
700    1_
$a Smerdon, S J $u Structural Biology of DNA-damage Signalling Laboratory, The Francis Crick Institute, London,UK.
700    1_
$a Macurek, L $u Department of Cancer Cell Biology, Institute of Molecular Genetics of the ASCR, Prague, Czech Republic.
700    1_
$a Hořejší, Z $u Department of Cancer Cell Biology, Institute of Molecular Genetics of the ASCR, Prague, Czech Republic. Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Centre, Charterhouse Square, London, UK.
773    0_
$w MED00003600 $t Oncogene $x 1476-5594 $g Roč. 36, č. 34 (2017), s. 4943-4950
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28436950 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171101105515 $b ABA008
999    __
$a ok $b bmc $g 1254458 $s 991892
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 36 $c 34 $d 4943-4950 $e 20170424 $i 1476-5594 $m Oncogene $n Oncogene $x MED00003600
LZP    __
$a Pubmed-20171025
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace